IL307954A - A method that allows immune system cells to penetrate tumors - Google Patents

A method that allows immune system cells to penetrate tumors

Info

Publication number
IL307954A
IL307954A IL307954A IL30795423A IL307954A IL 307954 A IL307954 A IL 307954A IL 307954 A IL307954 A IL 307954A IL 30795423 A IL30795423 A IL 30795423A IL 307954 A IL307954 A IL 307954A
Authority
IL
Israel
Prior art keywords
tumors
immune cells
cells infiltration
allowing immune
allowing
Prior art date
Application number
IL307954A
Other languages
English (en)
Hebrew (he)
Inventor
Mario Filion
Original Assignee
Alethia Biotherapeutics Inc
Mario Filion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alethia Biotherapeutics Inc, Mario Filion filed Critical Alethia Biotherapeutics Inc
Publication of IL307954A publication Critical patent/IL307954A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL307954A 2021-04-27 2021-04-27 A method that allows immune system cells to penetrate tumors IL307954A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2021/050572 WO2022226623A1 (en) 2021-04-27 2021-04-27 Method for allowing immune cells infiltration in tumors

Publications (1)

Publication Number Publication Date
IL307954A true IL307954A (en) 2023-12-01

Family

ID=83846453

Family Applications (2)

Application Number Title Priority Date Filing Date
IL307954A IL307954A (en) 2021-04-27 2021-04-27 A method that allows immune system cells to penetrate tumors
IL307961A IL307961A (en) 2021-04-27 2022-04-26 A method that allows immune system cells to penetrate tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL307961A IL307961A (en) 2021-04-27 2022-04-26 A method that allows immune system cells to penetrate tumors

Country Status (10)

Country Link
US (2) US20240199758A1 (cg-RX-API-DMAC10.html)
EP (2) EP4329801A4 (cg-RX-API-DMAC10.html)
JP (2) JP2024516416A (cg-RX-API-DMAC10.html)
KR (2) KR20240014052A (cg-RX-API-DMAC10.html)
CN (2) CN117479955A (cg-RX-API-DMAC10.html)
AU (2) AU2021442702A1 (cg-RX-API-DMAC10.html)
CA (2) CA3173786A1 (cg-RX-API-DMAC10.html)
IL (2) IL307954A (cg-RX-API-DMAC10.html)
MX (2) MX2023012766A (cg-RX-API-DMAC10.html)
WO (2) WO2022226623A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4329801A4 (en) * 2021-04-27 2025-05-14 Alethia Biotherapeutics Inc. Method for allowing immune cells infiltration in tumors
EP4475885A4 (en) * 2022-02-07 2026-02-18 Alethia Biotherapeutics Ulc POLYTHERAPY INTENDED FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN118914553B (zh) * 2024-07-22 2025-03-18 西安医学院第一附属医院 一种结直肠腺瘤和结直肠癌早期筛查的生物标志物的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1882A (en) 1872-12-11 Angus. Campbell A towel hanger
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
CA2928846A1 (en) * 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
CA2862739A1 (en) * 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
EP4329801A4 (en) * 2021-04-27 2025-05-14 Alethia Biotherapeutics Inc. Method for allowing immune cells infiltration in tumors

Also Published As

Publication number Publication date
KR20240013743A (ko) 2024-01-30
IL307961A (en) 2023-12-01
WO2022226637A1 (en) 2022-11-03
KR20240014052A (ko) 2024-01-31
CA3173786A1 (en) 2022-10-27
CN117479956A (zh) 2024-01-30
AU2022266854A1 (en) 2023-11-30
EP4329801A1 (en) 2024-03-06
JP2024516416A (ja) 2024-04-15
EP4329801A4 (en) 2025-05-14
WO2022226623A1 (en) 2022-11-03
AU2021442702A1 (en) 2023-11-30
EP4329802A1 (en) 2024-03-06
CN117479955A (zh) 2024-01-30
MX2023012768A (es) 2023-11-13
US20240317884A1 (en) 2024-09-26
US20240199758A1 (en) 2024-06-20
JP2024516818A (ja) 2024-04-17
CA3173797A1 (en) 2023-10-05
AU2022266854A9 (en) 2023-12-07
MX2023012766A (es) 2024-02-23
EP4329802A4 (en) 2025-09-03

Similar Documents

Publication Publication Date Title
IL307961A (en) A method that allows immune system cells to penetrate tumors
EP3906096A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER WITH IMMUNE CELLS
IL304275A (en) Cancer treatment methods
EP3619302A4 (en) COMPOSITIONS AND METHODS OF GENEDITATION IN T CELLS USING CRISPR / CPF1
IL312680A (en) Cancer treatment methods
IL280387A (en) A method for producing cells derived from dental pulp
IL276303A (en) Methods of treating cancer with ANTI-PD-1 antibodies
ZA202102652B (en) Methods for shrinking pituitary tumors
ZA202105316B (en) System and method for determining carryback in surface haulage
SG11202104963WA (en) Methods for manipulating cell state transitions in cancer
IL310495A (en) Methods for rapid infiltration of 3D scaffold proteins with cells
IL314713A (en) Combined therapy for colorectal carcinoma
PL3931675T3 (pl) Narzędzie i sposób rysowania krzywych 3d w 2d
EP3988175A4 (en) Method for treating malignant tumor
PL4048284T4 (pl) Metoda leczenia nowotworów
IL318302A (en) Methods for AT2 cell differentiation
HK40109536A (en) Method for allowing immune cells infiltration in tumors
HK40108569A (en) Method for allowing immune cells infiltration in tumors
ZA202106010B (en) Hybrid boiler-dryer and method
EP4003390A4 (en) METHOD FOR TREATING SOLID TUMORS
EP3928357A4 (en) METHOD FOR REDUCING THERMOMECHANICAL STRESS IN SOLAR CELLS
GB2634321B (en) Method for 3D design
GB202219317D0 (en) Methods for improving mitophagy in subjects
GB201907663D0 (en) Method for diagnosing colorectal cancer
GB202111761D0 (en) Methods for preparing oxazoborolidines